Related Experiment Video
Updated: Jun 30, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions.
Heather A Hostetler1, Lindsay R Syler, Lindy N Hall
1Department of Physiology and Pharmacology, Texas A&M University, TVMC, College Station, Texas 77843-4467, USA.
Journal of Biomolecular Screening
|September 25, 2008
Summary
Researchers screened 1040 compounds to find new diabetes treatments. They identified potential drugs that regulate peroxisome proliferator-activated receptor-alpha (PPARalpha) activity, offering hope for combating hyperglycemic cellular injury.
Area of Science:
- Biochemistry
- Endocrinology
- Pharmacology
Background:
- High glucose and fatty acid levels can hyperactivate PPARalpha, a key factor in diabetes-related cellular injury.
- Understanding PPARalpha's role is crucial for developing effective diabetes therapeutics.
- Identifying novel pathways involved in hyperglycemic damage is a primary research goal.
Purpose of the Study:
- To screen a library of 1040 compounds for antidiabetic properties.
- To identify agents that modulate PPARalpha activity under high glucose conditions.
- To discover new therapeutic strategies for preventing or reversing hyperglycemic cellular injury.
Main Methods:
- A high-throughput fluorescent binding assay was developed to assess compound effects on PPARalpha lipid binding.
- Compounds were screened for direct binding affinity to PPARalpha (nM K(d)s).
- PPARalpha transactivation was evaluated in the presence of high glucose and clofibrate.
Main Results:
- Approximately 1% of screened compounds restored PPARalpha acyl-CoA binding by over 60% in high glucose.
- These compounds demonstrated high-affinity direct interaction with PPARalpha.
- One compound effectively reversed PPARalpha hyperactivation induced by clofibrate and high glucose.
Conclusions:
- Novel compounds targeting PPARalpha have been identified as potential antidiabetic agents.
- These findings offer a new therapeutic avenue for managing diabetes-related cellular damage.
- Further research into these compounds could lead to innovative diabetes treatments.
